ArticleOncology reports2018
Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma.
Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Prognostic significance of macrophage migration inhibitory factor expression in cancer patients: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Integrating single-cell analysis and digital pathology for risk stratification in pancreatic cancer.Clinical & experimental metastasis · 2026Article
- Distinct Inflammatory and Dissemination Signatures Defined by Macrophage Migration Inhibitory Factor (MIF), Interleukin-8 (IL-8/CXCL8), and Stem Cell Factor (SCF) in Pancreatic Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Single-cell transcriptome analysis identifies MIF as a novel tumor-associated neutrophil marker for pancreatic ductal adenocarcinoma.NPJ precision oncology · 2025Article
- Macrophage migration inhibitory factor (MIF) and the tumor ecosystem: a tale of inflammation, immune escape, and tumor growth.Frontiers in immunology · 2025Review
- Exploring the role of antigen-presenting cancer-associated fibroblasts and CD74 on the pancreatic ductal adenocarcinoma tumor microenvironment.Medical oncology (Northwood, London, England) · 2024Review
- Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities.International journal of molecular sciences · 2024Review
- Macrophage migration inhibitory factor (MIF) predicts survival in patients with clear cell renal cell carcinoma.The journal of pathology. Clinical research · 2024Article
- Crosstalk of nervous and immune systems in pancreatic cancer.Frontiers in cell and developmental biology · 2023Review
- OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases.Journal for immunotherapy of cancer · 2022Review
- Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers.Biomolecules · 2022Review
- Homotypic cell-in-cell structures as an adverse prognostic predictor of hepatocellular carcinoma.Frontiers in oncology · 2022Article
- The Aging-Related Prognostic Signature Reveals the Landscape of the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells.Frontiers in oncology · 2022Article
- Macrophage migration inhibitory factor modulates proliferation, cell cycle, and apoptotic activity in head and neck cancer cell lines.Journal of dental sciences · 2021Article
- Targeting Macrophage Migration Inhibitory Factor in Acute Pancreatitis and Pancreatic Cancer.Frontiers in pharmacology · 2021Review
- Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma.Oncoimmunology · 2021Article
- Targeting Adipokines in Obesity-Related Tumors.Frontiers in oncology · 2021Review
- Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?Molecules (Basel, Switzerland) · 2020Review
- From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer.Cells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage migration inhibitory factor (MIF) is a pro‑inflammatory cytokine that serves important roles in cancer. MIF overexpression is frequently observed in numerous human cancer types, including pancreatic carcinoma. However, the prognostic value and function of MIF in pancreatic ductal adenocarcinoma (PDAC) have not been fully elucidated. In the present study, upregulation of MIF expression in PDAC tissue compared with adjacent normal tissue was observed. Furthermore, MIF overexpression was identified to be significantly associated with poor survival rates in patients with PDAC. Multivariate Cox regression analysis confirmed that MIF was an independent risk factor for poor survival. Functional analyses demonstrated that MIF knockdown significantly inhibited the proliferation and invasion of pancreatic cancer cells in vitro compared with control cells. IN addition, mechanistic investigations revealed that silencing MIF leads to inhibition of AKT serine/threonine kinase and extracellular‑signal‑regulated kinase activation, and suppression of cyclin D1 and matrix metalloproteinase‑2 expression, which may suppress tumor proliferation and invasion. These results highlight the importance of MIF overexpression in PDAC aggressiveness, and indicate that MIF may be a potential therapeutic target for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.